2[1]Fishman RS, Chambers R, Shapiro DA. Insulin administrationvia the Aerodose(TM) inhaler: comparison to subcutaneously injected insulin. Diabetes 2000;49.
3[2]Owens D R. Human Insulin: Clinical Pharmacological Studies in Normal Man. Lancaster: MTP Press, England. 1986. 138～ 144.
4[3]Drejer k, Bech A, Hansan P. Intranasal administration of insulin with phosolipid as absorption enhancer. Diabetic Med, 1992;9:335 ～ 340.
5Gmnell M,Savage DB,Chatterjee VK, et al. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation [ J ]. J Clin Endocrinol Metab, 2003, 88(6) :2412 - 2421.
6Stumvoll M. Thiazolidinediones- some recent developments[J]. Expert Opin Investig Drugs, 2003, 12(7): 1179 -1187.
7Wilmsen HM, Ciaraldi TP, Carter L, et al. Thaiazohdinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects[J]. Am J Physiol Endocrinol Metab, 2003, 285(2) :E354- E362.
8Verges B. Clinical interest of PPARs ligands[J]. Diabetes Metab, 2004, 30(1):7-12.
9Wang M, Tafuri S. Modulation of PPARγ activity with pharmaceutical agents: treatment of insulin resistarme and atherosclerosis[J]. J Cell Biochem, 2003, 89(1) :38 -47.
10Doggrell S. Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs [ J ] ? Expert Opin Imestig Drugs, 2003,12(4) :713 - 716.
